Status:
RECRUITING
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Microbiome
Immune Function
Eligibility:
All Genders
18-100 years
Brief Summary
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patient...
Detailed Description
Methods: Bronchoalveolar lavage specimens of patients with anti-MDA5 antibody positive dermatomyositis and interstitial lung disease were collected and studied to analyze the relationship between the ...
Eligibility Criteria
Inclusion
- Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive.
- Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.
- Must have undergone bronchoalveolar lavage.
- Age≥18 years old.
- Patients who signed informed consent forms
Exclusion
- Patients who had other connective tissue diseases.
- Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.
- Pregnant or lactating patients.
- The patient also participated in any other clinical trial.
- Disagreement for inclusion in this study
Key Trial Info
Start Date :
January 20 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 25 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06203249
Start Date
January 20 2024
End Date
November 25 2026
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PLA
Beijing, Beijing Municipality, China, 100853